WO2000061171A2 - Uses of mammalian ox2 protein and related reagents - Google Patents
Uses of mammalian ox2 protein and related reagents Download PDFInfo
- Publication number
- WO2000061171A2 WO2000061171A2 PCT/US2000/009719 US0009719W WO0061171A2 WO 2000061171 A2 WO2000061171 A2 WO 2000061171A2 US 0009719 W US0009719 W US 0009719W WO 0061171 A2 WO0061171 A2 WO 0061171A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mammalian
- tissue
- protein
- antagonist
- agonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Definitions
- soluble or membrane proteins play a critical role in regulating cellular interactions. These proteins also mediate cellular activities in many ways. They have been shown, in many cases, to modulate proliferation, growth, and differentiation of hematopoietic stem cells into the vast number of progenitors composing the lineages responsible for an immune response. Others are important mediators of intercellular signaling, often as receptors or ligands. They are also quite important in immunological responses and physiology.
- Different methods are provided, e.g., of modulating the activation of a leukocyte in a tissue, the method comprising contacting myeloid or monocyte/macrophage lineage cells in the tissue with: an agonist of a mammalian 0X2 protein; or an antagonist of a mammalian 0X2 protein.
- the modulating is inhibiting the leukocyte cell, and the contacting is with the agonist.
- the administering is often in combination with: an anti-inflammatory cytokine agonist or antagonist; an analgesic; an anti-inflammatory agent; or a steroid.
- the modulating is enhancing, and the contacting is with the antagonist.
- the administering may be in combination with: an angiogenic factor; a growth factor, including FGF or PDGF; an antibiotic or antiviral; or a clotting factor.
- macrophage activation In settings where macrophage activation is desired, e.g., wound healing, some aspects of healing in CNS injury, etc., blocking of 0X2 or using an OX2R antagonist would be beneficial. Release from the typical suppression will result in quicker or more pronounced activation. Enhanced granulocyte activity would also be beneficial for control of bacterial infection. Conversely, in situations where macrophage activation should be suppressed, e.g., inflammation such as seen in rheumatoid arthritis, activation of the OX2R by agonists, e.g., a recombinant soluble 0X2 in a multivalent form that can cross-link the OX2R, could be useful. This would delay or prevent release from active suppression.
- agonists e.g., a recombinant soluble 0X2 in a multivalent form that can cross-link the OX2R
- Proteins or peptides having substantial amino acid sequence homology with the amino acid sequence of the 0X2 protein are also contemplated.
- the variants include species or allelic variants. Homology, or sequence identity, is defined in, e.g., U.S.S.N. 08/250,846; U.S.S.N. 08/177,747; U.S.S.N. 08/077,203; PCT/US95/00001 ; Needleham, et al. (1970) J. Mol. Biol. 48:443-453; Sankoff, et al. (1983) Chapter One in Time Warps. String Edits, and Macromolecules: The Theory and Practice of
- Immunogenetics 25:329-335 Standard hybridization methods can be used, or PCR primers constructed to isolate the clone. Entrez accession numbers for both the nucleotide and amino acid sequences are provided above.
- Recombinant protein may be purified using standard procedures. Affinity chromatography of epitope tagged fusion protein may be utilized.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002369454A CA2369454A1 (en) | 1999-04-13 | 2000-04-12 | Uses of mammalian ox2 protein and related reagents |
AU43413/00A AU4341300A (en) | 1999-04-13 | 2000-04-12 | Novel uses of mammalian ox2 protein and related reagents |
JP2000610503A JP2002541210A (en) | 1999-04-13 | 2000-04-12 | Novel use of mammalian OX2 protein and related reagents |
EP00923257A EP1171154A2 (en) | 1999-04-13 | 2000-04-12 | Uses of mammalian ox2 protein and related reagents |
MXPA01010480A MXPA01010480A (en) | 1999-04-13 | 2000-04-12 | Novel uses of mammalian ox2 protein and related reagents. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29082599A | 1999-04-13 | 1999-04-13 | |
US09/290,825 | 1999-04-13 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2000061171A2 true WO2000061171A2 (en) | 2000-10-19 |
WO2000061171A3 WO2000061171A3 (en) | 2001-01-25 |
WO2000061171A9 WO2000061171A9 (en) | 2002-01-03 |
Family
ID=23117713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/009719 WO2000061171A2 (en) | 1999-04-13 | 2000-04-12 | Uses of mammalian ox2 protein and related reagents |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1171154A2 (en) |
JP (1) | JP2002541210A (en) |
AR (1) | AR023464A1 (en) |
AU (1) | AU4341300A (en) |
CA (1) | CA2369454A1 (en) |
MX (1) | MXPA01010480A (en) |
WO (1) | WO2000061171A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8236309B2 (en) | 2001-10-12 | 2012-08-07 | Schering Corporation | Use of bispecific antibodies to regulate immune responses |
WO2023079278A1 (en) | 2021-11-03 | 2023-05-11 | Ducentis Biotherapeutics Limited | Novel proteins |
WO2023214387A1 (en) | 2022-05-06 | 2023-11-09 | Ducentis Biotherapeutics Limited | Novel cd200 fusion proteins |
WO2023214388A1 (en) | 2022-05-06 | 2023-11-09 | Ducentis Biotherapeutics Limited | Novel cd200 fusion proteins |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201608197D0 (en) | 2016-05-10 | 2016-06-22 | Ducentis Biotherapeutics Ltd | Novel proteins |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997021450A1 (en) * | 1995-12-08 | 1997-06-19 | Brigham And Women's Hospital, Inc. | Ox-2 costimulatory molecule |
US5753218A (en) * | 1996-05-03 | 1998-05-19 | Schering Corporation | Method for treating inflammation |
US5859208A (en) * | 1988-07-06 | 1999-01-12 | Fiddes; John C. | Human basic fibroblast growth factor analog |
WO1999024565A1 (en) * | 1997-11-07 | 1999-05-20 | Transplantation Technologies Inc. | Methods and compositions for immunomodulation |
-
2000
- 2000-04-12 MX MXPA01010480A patent/MXPA01010480A/en unknown
- 2000-04-12 WO PCT/US2000/009719 patent/WO2000061171A2/en not_active Application Discontinuation
- 2000-04-12 EP EP00923257A patent/EP1171154A2/en not_active Withdrawn
- 2000-04-12 JP JP2000610503A patent/JP2002541210A/en not_active Withdrawn
- 2000-04-12 AR ARP000101685A patent/AR023464A1/en unknown
- 2000-04-12 AU AU43413/00A patent/AU4341300A/en not_active Abandoned
- 2000-04-12 CA CA002369454A patent/CA2369454A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5859208A (en) * | 1988-07-06 | 1999-01-12 | Fiddes; John C. | Human basic fibroblast growth factor analog |
WO1997021450A1 (en) * | 1995-12-08 | 1997-06-19 | Brigham And Women's Hospital, Inc. | Ox-2 costimulatory molecule |
US5753218A (en) * | 1996-05-03 | 1998-05-19 | Schering Corporation | Method for treating inflammation |
WO1999024565A1 (en) * | 1997-11-07 | 1999-05-20 | Transplantation Technologies Inc. | Methods and compositions for immunomodulation |
Non-Patent Citations (2)
Title |
---|
NI J ET AL: "An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant which prolongs allograft survival." FASEB JOURNAL, vol. 13, no. 5 PART 2, 15 March 1999 (1999-03-15), page A983 XP000960581 Annual Meeting of the Professional Research Scientists on Experimental Biology 99;Washington, D.C., USA; April 17-21, 1999 ISSN: 0892-6638 * |
RAGHEB RAFIK ET AL: "Preparation and functional properties of monoclonal antibodies to human, mouse and rat OX-2." IMMUNOLOGY LETTERS, vol. 68, no. 2-3, 1 June 1999 (1999-06-01), pages 311-315, XP000960642 ISSN: 0165-2478 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8236309B2 (en) | 2001-10-12 | 2012-08-07 | Schering Corporation | Use of bispecific antibodies to regulate immune responses |
WO2023079278A1 (en) | 2021-11-03 | 2023-05-11 | Ducentis Biotherapeutics Limited | Novel proteins |
WO2023214387A1 (en) | 2022-05-06 | 2023-11-09 | Ducentis Biotherapeutics Limited | Novel cd200 fusion proteins |
WO2023214388A1 (en) | 2022-05-06 | 2023-11-09 | Ducentis Biotherapeutics Limited | Novel cd200 fusion proteins |
Also Published As
Publication number | Publication date |
---|---|
AU4341300A (en) | 2000-11-14 |
JP2002541210A (en) | 2002-12-03 |
CA2369454A1 (en) | 2000-10-19 |
WO2000061171A3 (en) | 2001-01-25 |
WO2000061171A9 (en) | 2002-01-03 |
MXPA01010480A (en) | 2002-03-27 |
EP1171154A2 (en) | 2002-01-16 |
AR023464A1 (en) | 2002-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20020192215A1 (en) | Novel uses of mammalian OX2 protein and related reagents | |
ES2149149T3 (en) | PROTEINAS DE UNION A INTERLEUQUINA-18, ITS PREPARATION AND USE. | |
JP5379107B2 (en) | BAFF receptor (BCMA), an immune regulator | |
US20120141456A1 (en) | Use of DR6 and p75 Antagonists to Promote Survival of Cells of the Nervous System | |
WO2008063849A2 (en) | Multiple sclerosis therapy | |
WO2007098283A2 (en) | Use of antagonists of maif receptor complex molecules and neurotrophic factors for treatment of neurological diseases and disorders | |
EP1326974B1 (en) | Methods of using a human il-17-related polypeptide to treat disease | |
EP2429584A2 (en) | Methods and compositions for treatment | |
US20020138860A1 (en) | Novel uses of mammalian CCR6 receptors and related reagents | |
WO2000061171A2 (en) | Uses of mammalian ox2 protein and related reagents | |
US9352038B2 (en) | Treatment of neurological conditions | |
US20150329638A1 (en) | Use of DR6 Antagonists to Improve Motor Neuron Disease | |
CA2235951C (en) | Novel uses of mammalian ctla-8 and related reagents | |
KR20000075732A (en) | Lymphocyte activation inhibitors | |
Hasegawa et al. | Monoclonal antibodies to epitope of CD45R (B220) inhibit interleukin 4-mediated B cell proliferation and differentiation | |
AU705281B2 (en) | Secreted human fas antigen | |
WO1996020206A9 (en) | Secreted human fas antigen | |
US6063372A (en) | Uses of mammalian CTLA-8 and related reagents | |
WO2001058484A2 (en) | Novel uses of mammalian ccr8 receptors and related reagents | |
WO1995002611A1 (en) | Cell surface protein present on nk (natural killer cells) named dx1 | |
US20030148369A1 (en) | Novel uses of mammalian CCR8 receptors and related reagents | |
US20060165689A1 (en) | Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations employing tirc7 | |
Sytwu | T cell activation, apoptosis, and autoimmune disease | |
US20080226654A1 (en) | Uses of mammalian cytokine; related reagents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase in: |
Ref document number: 2369454 Country of ref document: CA Ref country code: CA Ref document number: 2369454 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase in: |
Ref country code: JP Ref document number: 2000 610503 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/010480 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000923257 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1-4, SEQUENCE LISTING, ADDED |
|
WWP | Wipo information: published in national office |
Ref document number: 2000923257 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000923257 Country of ref document: EP |